To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Biogen is set to receive as much as $250 million in funding to develop a late-stage experimental lupus ...

and gain approval in Europe or Asia, it could dramatically increase revenue. The market for Alzheimer's drugs is already estimated at $5.2 billion and could almost double by 2030. Biogen ...

Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on Biogen (NASDAQ:BIIB) in the last three months. The following table summarizes their recent ...